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Abstract
Background: Nigeria is faced with a high burden of Human Immunodeficiency Virus (HIV) infection and multidrug-resistant
tuberculosis (MDR-TB). Treatment outcomes among MDR-TB patients registered across the globe have been poor, partly
due to high loss-to-follow-up. To address this challenge, MDR-TB patients in Nigeria are hospitalized during the intensive-
phase(IP) of treatment (first 6–8 months) and are provided with a package of care including standardized MDR-TB treatment
regimen, antiretroviral therapy (ART) and cotrimoxazole prophylaxis (CPT) for HIV-infected patients, nutritional and
psychosocial support. In this study, we report the end-IP treatment outcomes among them.
Methods: In this retrospective cohort study, we reviewed the patient records of all bacteriologically-confirmed MDR-TB
patients admitted for treatment between July 2010 and October 2012.
Results: Of 162 patients, 105(65%) were male, median age was 34 years and 28(17%) were HIV-infected; all 28 received ART
and CPT. Overall, 138(85%) were alive and culture negative at the end of IP, 24(15%) died and there was no loss-to-follow-
up. Mortality was related to low CD4-counts at baseline among HIV-positive patients. The median increase in body mass
index among those documented to be underweight was 2.6 kg/m2 (p,0.01) and CD4-counts improved by a median of
52 cells/microL among the HIV-infected patients (p,0.01).
Conclusions: End-IP treatment outcomes were exceptional compared to previously published data from international
cohorts, thus confirming the usefulness of a hospitalized model of care. However, less than five percent of all estimated
3600 MDR-TB patients in Nigeria were initiated on treatment during the study period. Given the expected scale-up of MDR-
TB care, the hospitalized model is challenging to sustain and the national TB programme is contemplating to move to
ambulatory care. Hence, we recommend using both ambulatory and hospitalized approaches, with the latter being reserved
for selected high-risk groups.
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Introduction
Multidrug-resistant tuberculosis (MDR-TB) is a growing public
health problem that jeopardizes the progress made in tuberculosis
care and control worldwide [1,2]. Globally, the prevalence of
MDR-TB is estimated to be 3.1% among new TB patients and
10% among previously treated patients [2]. In Nigeria, the
prevalence of MDR-TB is reported to be 2.9% among newly
detected cases and 14.5% in previously treated cases and the
number of MDR-TB patients is estimated to be between 2700 and
4500 [3,4].
In Nigeria, the prevalence of HIV is estimated to be 4.4% in the
general population and that among TB patients has increased
from 2.2% in 1991 to about 27% in 2008[5]. The prevalence of
HIV/MDR-TB co-infection in Nigeria, however, is not known to-
date. An individual patient data meta-analysis by Ahuja et al,
showed that ‘‘global MDR-TB treatment outcomes were poor:
treatment success was achieved in only slightly more than half of
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the patients’’ [6]. Treatment success was associated with overall
duration of treatment, number of effective drugs in the regimen,
and with use of later generation fluoroquinolones (levofloxacin,
moxifloxacin, gatifloxacin, and sparfloxacin)’’ but no association
with hospitalization or ambulatory approach during the intensive-
phase was examined. Several studies from settings in different
parts of the world reported 77 to 88% of patients converted
sputum culture to negative after a median of 2 to 3 months of
treatment initiation [6–9]. However, with the exception of South
Africa, very limited data are available on intensive-phase and
completed treatment outcomes from African cohorts.
There is ample evidence that ambulatory strategies for the
treatment of MDR-TB are considerably effective and use fewer
resources which is a major issue in countries with high disease
burden and limited resources [10]. The World Health Organiza-
tion (WHO) recommends ambulatory treatment for MDR-TB and
most national TB programmes have adopted an ambulatory
strategy. However, the National Tuberculosis Program in Nigeria
opted for an in-patient approach to allow for better adherence,
adequate monitoring of adverse reactions, regular sputum smear
and culture examination, provision of antiretroviral treatment
(ART) to HIV co-infected patients and multi-disciplinary attention
to the patients.
Our study aimed to assess the intensive-phase treatment
outcomes among all MDR-TB in-patients receiving treatment in
Nigeria. The specific objectives of the study were: 1) to describe
the clinical and demographic characteristics of the patients of the
Nigerian MDR-TB cohort; 2) to determine survival and smear
and culture conversion by the end of the intensive-phase of
treatment, stratified by HIV-status; and 3) to explore associations
between selected risk factors and treatment outcomes in this
cohort.
Methods
Ethics
Ethical approval was given by National Health Research Ethics
Committee of Nigeria in June, 2013. This study has also met the
Me´decins Sans Frontie`res Ethics Review Board (Geneva, Switzer-
land) approved criteria for analysis of routinely-collected program
data in May, 2013. It satisfies the requirements of the Ethics
Advisory Group of the International Union Against Tuberculosis
and Lung Disease, Paris, France. Patient information was
anonymized and de-identified prior to analysis. As this was a
routinely collected program data, informed consent from the
patients was not obtained. The named ethics committees approved
the study and waived the need for consent.
Study design
This was a retrospective cohort study using routinely collected
program data.
Setting and study population
Nigeria, the largest country in the western region of Africa is a
federation of 36 states and the Federal Capital Territory (FCT)
with 774 administrative units referred to as-Local Government-
Areas. The country has an estimated population of 154,729,000 by
WHO in 2009 [5]. More than half of Nigerians (54.4%) live in
poverty in spite of the huge revenues accruing from oil and gas.
The country is composed of more than 250 ethnic groups with
Yoruba, Igbo and Hausa being the most influential.-The health
system in Nigeria is structured along three levels, namely primary,
secondary and tertiary corresponding to the level of government
that are responsible for health-care services, local government, the
state, and the federal respectively. The-public and private-sectors
are partners in the delivery of health care throughout the country
[5].
Nigeria established its National TB and Leprosy Control
Program (NTBLCP) in 1989. The NTBLCP operates along the
three levels of government: National, State and Local Government
Areas, with coordinating offices at each level. Health facilities at
the peripheral level are the operational units of DOTS services. As
of 2009, there were 3,455 health facilities providing free TB and
DOTS services in Nigeria [11].
Currently, there are seven hospitals for MDR treatment in
Nigeria. Of them, only five were functional during the study
period which included the following: University College Hospital,
Ibadan with 23 beds, General Chest Hospital, Jericho-Ibadan,
with 24 beds, Infectious Diseases Hospital, Yaba-Lagos, with 40
beds, Lawrence Henshaw Hospital, Calabar with 14 beds and
National Tuberculosis and Leprosy Training School, Zaria with
40 beds. There were no other hospitals in the public or private
health sector providing MDR-TB treatment at the time of the
study.
Infection control measures at the hospital wards, including
environmental and administrative measures, were designed to
prevent nosocomial transmission. In general, there were ventila-
tors in all the wards and staff used N95 respirator whenever they
came in contact with the patients irrespective of the culture status.
In one of the facilities, there were cubicles where patients with
culture conversion were moved to avoid re-infection.
Patient’s admission process
All diagnosed MDR-TB patients were first registered on a
waiting list, given the limitation in the availability of hospital beds.
Patients were notified by phone or during home visits as and when
beds became available. Those patients who fully understood the
need for long hospitalization and signed an informed consent form
were finally admitted and initiated on treatment. The cost for
hospital stay and treatment was covered by the programme.
National MDR-TB treatment protocol
All bacteriologically confirmed MDR-TB patients received
intensive phase for 6–8 months in the hospital, followed by 12
months of continuation phase in the community, based on the
WHO updated guidelines in 2011[12]. A standardized treatment
regimen was used, including five drugs: Kanamycin/Amikacin,
Levofloxacin, Prothionamide, Cycloserine, Pyrazinamide (with
Pyridoxine). Baseline investigations were done for patients
admitted. Sputum smear microscopy and culture examinations
were performed every month to monitor bacteriological response
to treatment.
While the patients were admitted for MDR-TB treatment, they
were supported by non-governmental organizations which pro-
vided complete nutritional support (three nutritionally balanced
meals were served to each patient daily), stipends to make phone
calls to their homes and provision of recreation activities such as
games, books and films. Family and friends were allowed to visit
in-patients over the weekend.
Data collection and analysis
Demographic and clinical information of all MDR-TB patients
admitted between July 2010 and October 2012 were extracted
from the standardized program registers and double-entered into a
Microsoft excel database, validated, subsequently imported into
EpiData (version 2.2.2.182, EpiData Association, Odense, Den-
mark) for analysis.
Intensive Outcome of Multidrug-Resistant TB
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The demographic and clinical characteristics of MDR-TB
patients were described using proportions and median, as
applicable. Chi-square test was used to compare differences in
outcomes (death, culture conversion) between HIV/MDR-TB co-
infected and non-co-infected patients. Survival curves were plotted
for the time to sputum smear and culture conversion and time to
death among the patients. We examined associations of sex, age,
body mass index (BMI),CD4-count and HIV-status with adverse
outcomes (defined as death and non-culture conversion) using chi
square or Kruskal Wallis test as appropriate.
Results
Patient characteristics
Between July 2010 and October 2012, there were 162
bacteriologically confirmed MDR-TB patients admitted for
treatment in five centres in Nigeria. Baseline and clinical
characteristics of the patients in relation to their HIV-status are
shown in Table 1. Sixty five per cent of the MDR-TB patients
were males and median age was 34 years (Interquartile range
(IQR): 29 – 42). About half (52%) of the patients were referred
from the South West Zone of Nigeria.
Twenty-eight (17%)of all the MDR-TB patients were co-
infected with HIV, and over the course of the second line TB
treatment all were on cotrimozaxole prophylaxis and antiretroviral
treatment. Approximately half (46%) were underweight on
admission. No statistical differences were observed in demographic
and baseline clinical characteristics between HIV-infected and
uninfected patients.
End of intensive-phase treatment outcomes
Survival. Among all patients initiated on treatment, 24(15%)
patients died and the remaining 138 (85%) were alive and on
treatment at the end of the intensive phase. No patients were
lost-to-follow-up in the Nigerian MDR-TB cohort. The timing of
the deaths is indicated in Figure 1: the survival curve reflects early
mortality in the first few weeks of treatment, and an overall higher
proportion of deaths occurred among the HIV co-infected
patients. After testing for associations with baseline socio-
demographic and clinical factors, only baseline CD4-count was
found to be significantly associated with death (median difference;
109 cells/microL, P,0.03).
Smear and culture conversion. All of the 138 patients who
were alive at the end of intensive phase had become sputum smear
and culture negative. Kaplan-Meier curves showing the timing of
sputum smear and culture conversion, stratified by HIV-status, are
shown in Figure 2.There was no statistically significant difference
in the time to sputum smear and culture conversion among HIV
positive and negative individuals.
Clinical/nutritional and immunological
recovery. Seventy four (46%) of the patients were underweight
at the time of treatment initiation compared to 15 (9%) at the end
of hospitalisation. Among patients who were underweight at
baseline, a median gain in BMI of 2.6 Kg/m2 and 3.3 Kg/m2 was
noted among HIV-positive and HIV-negative patients, respec-
tively. Among HIV patients the median CD4-counts were
415 cells/microL at baseline and 491 cells/microL at six months.
A median (IQR) CD4-count increase of 52 cells/mircoL (44–71)
was observed, shown in Table 2.
Discussion
Based on a review of the current literature, we noted that only a
limited number of MDR-TB cohorts from Africa have been
described, all of which from South Africa [6,13,14]. This is the first
report on MDR-TB treatment outcomes from Nigeria, a country
with a large burden of TB and a large number of MDR-TB
patients (based on the WHO estimates). This national cohort is
Table 1. Demographic and clinical characteristics of hospitalized MDR-TB patients in Nigeria, July 2010-October 2012.
Variable HIV-positive N (%) HIV-negative N (%) P-value
Total 28 134
Age(yr)
# 24 2 (7) 17 (13) 0.3
25 – 44 23 (82) 89 (66)
$ 45 3 (11) 28 (21)
Sex
Male 22 (79) 83 (62) 0.09
Female 6 (21) 51 (38)
Registration group
Failure of 1st Treatment 5 (18) 13 (10) 0.2
Failure of Re-treatment 23 (82) 121 (90)
Pre-treatment BMI (kg/m2)
Underweight (, 18.5) 13 (46) 61 (46) 0.7
Normal/overweight ($ 18.5) 13 (46) 70 (52)
Unknown 2 (7) 3 (2)
Pre-treatment CD4 count (cells/microL) *
, 350 8 (29) NA NA
350 – 499 14 (50) NA
$ 500 6 (21) NA
doi:10.1371/journal.pone.0094393.t001
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relatively small, but we report successful results in terms of
survival, culture conversion and retention in care among HIV-
infected and uninfected patients who were hospitalized throughout
the intensive phase of treatment. We recorded no losses to follow-
up in this cohort, a significant finding. Moreover, satisfactory
clinical and immunological outcomes were recorded among HIV
co-infected patients.
There was a trend towards overall poorer outcomes in HIV-
infected individuals, with significant mortality in the first few weeks
after treatment initiation; these results were consistent with
previous studies showing increased mortality in HIV-positive
compared to HIV-negative patients with drug-susceptible TB [13–
15]. However, this difference was not found to be statistically
significant owing to small numbers.
Programme achievements
The end of intensive-phase treatment outcomes recorded so far
in the program demonstrates the effectiveness of treating MDR-
TB patients in a hospital setting. Some unique findings of this
study included the exceptionally high retention in care among all
patients and high up-take of ART among HIV co-infected patients
(both 100%). While the exact reasons for this achievement are not
clear, we speculate that the following factors may have contributed
to these results: first, all patients received fully supervised DOT
throughout the course of the intensive phase as this was feasible in
a hospital setting. Second, there was intensive monitoring, early
diagnosis of adverse events (including systematic and on-request
clinical and laboratory assessment) and prompt management.
Third, a full package of psychosocial services was offered to all
hospitalized patients, which included nutritional support, individ-
ual counselling, and opportunities for recreational activities. We
further suggest that the hospitalization (isolation) of patients and
especially during the early days of treatment may have contributed
to prevention of spread of the resistant strains to the community.
Ambulatory and Hospital-based treatment strategies and
policy implications
The study findings revoke the debate between hospitalized and
ambulatory models of care for MDR-TB patients. According to
the WHO, ‘‘the choice between hospitalization and ambulatory
treatment depends on several factors in addition to the severity of
the disease. Such factors include the availability of hospital beds
with adequate infection control measures, the availability of
trained personnel to administer treatment and manage adverse
drug reactions; a social support network to facilitate adherence to
ambulatory treatment; and the presence of other clinical or social
conditions for in-patients.’’ [16]
In most settings, the community-based model of treatment is
more feasible owing to the resource constraints faced by high TB
burden countries [10,17–19]. However, a major challenge in these
models is the high loss-to-follow up reported [10,17–19]. In our
setting we have recorded no losses to follow-up, thus favouring the
‘hospitalization’ approach for treating MDR-TB patients. But this
might be due to the relatively small scale of the programme and a
highly selected cohort of patients. We hypothesize that the
retention in care and treatment adherence may not be similar
during the continuation (ambulatory) phase of treatment. Findings
from countries of Eastern Europe with similar approaches to
hospitalization during the intensive phase indicate a high
treatment adherence during hospitalization, but this high adher-
ence was not sustained in the ambulatory, continuation phase
[20].
WHO estimates there are currently about 3600 MDR-TB cases
annually among the notified pulmonary TB patients in Nigeria. Of
this, only 162 (,5%) patients have been treated hitherto and this
could be partially due to the limited capacity of the hospitalization
model. This is further substantiated by the fact that a number of
MDR-TB patients are in the waiting-list for treatment, due to lack
of hospital beds.
Nigeria is rapidly expanding the provision of the new Xpert
MTB/RIF test and, given that this test automatically tests for
rifampicin resistance, it is expected that the need for hospital beds
will soon increase exponentially. Mandatory hospitalization may
become a major bottleneck for rapid scale-up of treatment unless
resources are immediately allocated to increase capacity both in
terms of infrastructure and in terms of trained human resources.
Currently, the Nigerian National Tuberculosis Programme (NTP)
is moving towards an ambulatory approach for both intensive and
continuation phase in response to this anticipated increase. This
approach will also require considerable resources in order to
maintain such good outcomes. Despite all these limitations of a
hospitalized model of care, the fact remains that this is effective in
Figure 1. Survival among hospitalized MDR-TB patients stratified by HIV-status in Nigeria, July 2010 – October 2012.
doi:10.1371/journal.pone.0094393.g001
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Figure 2. a. Time to sputum smear conversion among hospitalized MDR-TB patients stratified by HIV-status in Nigeria, July 2010 – October 2012.
b.Time to culture conversion among hospitalized MDR-TB patients stratified by HIV-status in Nigeria, July 2010 – October 2012.
doi:10.1371/journal.pone.0094393.g002
Table 2. End of Intensive phase treatment outcomes of hospitalized MDR–TB patients in Nigeria July 2010 – October, 2012.
Outcome HIV-positive N (%) HIV-negative N (%) P-value
Clinical Outcomes
Alive, on treatment and culture negative 21 (75) 117 (87) 0.1
Dead 7 (25) 17 (13)
Loss to follow-up 0 0
BMI gained among underweight patients at baseline
(Kg/m2)
Median (IQR) 2.6 (1.8–2.9) 3.3 (2.5–4.4) 0.01
CD4- count gained(cells/microL)
Median (IQR) 52 (42–71) N/A N/A
doi:10.1371/journal.pone.0094393.t002
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ensuring patient compliance to treatment, a major challenge in
ambulatory care. Hence, it could be possible to adopt the best of
both models of care with hospitalized approach used for select
groups of patients with known high risk of loss to follow-up and
mortality (like HIV-infected MDR-TB patients).
Based on the existing experiences from settings that have opted
for ambulatory strategies and which are characterized by high loss
to follow-up, we call for increased resources and innovative
support strategies, including a patient-centred approach which
includes nutritional and psychosocial support, in the management
of MDR-TB patients.
Limitations
There are several limitations to our study. First, the size of this
observational cohort is relatively small. However, this represents
all patients treated in Nigeria during the study period. Further,
most MDR-TB cohorts reported till date are of small size. Second,
we acknowledge that we only report on interim rather than final
treatment outcomes, but still we think our data may contribute to
the knowledge base. Third we acknowledge that this may have
been a highly selective cohort with only those patients consenting
to be hospitalized for the entire duration for intensive phase
included in the study cohort; the selection procedure precluded the
representativeness of our study populations. Fourth, as we report
on a treatment cohort and not on-diagnosis cohort the adverse
events may be significantly underestimated. It is documented that
pre-treatment mortality and losses to follow-up are very high
among HIV patients [21–27]. This was compounded by the strict
selection procedure described.
Despite these limitations, this report provides some important
evidence on the effectiveness, especially in terms of retention in
care, of a hospital-based MDR-TB treatment model in HIV-
infected and uninfected patients. Moreover, it provides insights
that feed into the ongoing discussions about effectiveness and
scalability.
Conclusions, policy implications
The current approach to MDR-TB care in Nigeria which
includes hospitalization in IP was found to be effective in ensuring
treatment adherence with no loss to follow-up and high proportion
alive and culture negative at the end of the IP. However, given
that only less than 5% of all estimated MDR-TB patients are
currently initiated on treatment and the expected increase in
demand for hospital beds owing to implementation of Xpert
MTB-RIF and rapid increases in MDR-TB case detection, this
model may be challenging to sustain. Nigerian NTP, thus is
contemplating to move to the model of ambulatory treatment.
However, we recommend using both ambulatory and hospitalized
approaches, with the latter being reserved for MDR-TB patients
with higher risk of poor outcomes. Policy makers and clinicians
should collaborate to find the best trade-off between excellent
retention in care and the need for massive and fast scale-up of
treatment, given high disease burden and resource constraints in
Nigeria.
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